Devesh Patel, MD
Nephrology · Augusta, GANPI 1316902943
Payments from drug & device makers
Across 337 payments — averaging $827.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$152K
- Bayer$62K
- Amgen$39K
- Janssen Research & Development, LLC$22K
- Cipla USA Inc.$569
- Otsuka America Pharmaceutical, Inc.$442
- plus $4K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 45 | $152,268 |
| Bayer | 33 | $61,548 |
| Amgen(2 entities) | 44 | $38,887 |
| Janssen Research & Development, LLC | 3 | $21,509 |
| Cipla USA Inc. | 1 | $569 |
| Otsuka America Pharmaceutical, Inc. | 21 | $442 |
| Calliditas Therapeutics US Inc. | 17 | $410 |
| Mallinckrodt Hospital Products Inc. | 14 | $392 |
| Aurinia Pharma U.S., Inc. | 22 | $379 |
| Vifor Pharma, Inc. | 21 | $344 |
| Fresenius USA Marketing, Inc. | 17 | $278 |
| OPKO Pharmaceuticals, LLC | 15 | $272 |
| GSK | 16 | $251 |
| Daiichi Sankyo Inc. | 12 | $245 |
| Novartis | 9 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $181 |
| Travere Therapeutics, Inc. | 16 | $162 |
| Lilly USA, LLC | 3 | $70 |
| ANI Pharmaceuticals, Inc. | 3 | $57 |
| Akebia Therapeutics Inc | 2 | $45 |
| Novo Nordisk | 2 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Shire North American Group Inc | 2 | $30 |
| Cormedix Inc. | 1 | $29 |
| Pfizer | 1 | $27 |
| Mallinckrodt Enterprises LLC | 2 | $27 |
| Ardelyx, Inc. | 1 | $20 |
| Mannkind Corporation | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| AbbVie | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
How this compares
$278,771 in reported general payments places this provider in the 90th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Augusta
- Harold HubertAugusta$2.8M
- Barton BrezinaAugusta$1.5M
- Laura MulloyAugusta$891K
- Matthew DiamondAugusta$815K
- Don WilliamsonAugusta$116K
- Syed BabarAugusta$63K
- James StenardAugusta$13K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.